Comparative Pharmacology
Head-to-head clinical analysis: CARISOPRODOL AND ASPIRIN versus TRANCOPAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARISOPRODOL AND ASPIRIN versus TRANCOPAL.
CARISOPRODOL AND ASPIRIN vs TRANCOPAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carisoprodol is a centrally acting muscle relaxant that modulates GABA-A receptor activity and may act as a weak partial agonist at the central nervous system. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis, which results in analgesic, antipyretic, and anti-inflammatory effects.
Trancopal (chlormezanone) is a centrally acting muscle relaxant and anxiolytic. Its exact mechanism is not fully understood, but it is believed to act on the central nervous system by depressing polysynaptic reflexes and possibly through GABAergic modulation.
1-2 tablets (carisoprodol 200 mg / aspirin 325 mg) orally 4 times daily.
200-400 mg orally every 6 hours as needed for acute musculoskeletal pain; maximum 1.6 g per day.
None Documented
None Documented
Carisoprodol: 1.5-2 hours (terminal half-life), but active metabolite meprobamate has half-life of 9-12 hours, contributing to prolonged sedation. Aspirin: 15-20 minutes (parent drug); salicylate: 2-3 hours at low doses, 15-30 hours at high doses due to saturable hepatic metabolism.
Terminal elimination half-life: 20-30 hours in healthy adults. Prolonged in hepatic impairment (up to 60 hours).
Carisoprodol: Renal excretion of metabolites (hydroxycarisoprodol, meprobamate) and <1% unchanged. Aspirin: Renal excretion of salicylate and metabolites (salicyluric acid, gentisic acid); ~80% renal, with dose-dependent elimination via first-order and Michaelis-Menten kinetics.
Primarily renal: ~95% as metabolites (glucuronides, sulfate conjugates) with <1% unchanged. Fecal: <5%.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant